VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

← Back to Screener

National Research Corporation (NRC) Financial Ratios

30 years of historical data (1996–2025) · Healthcare · Medical - Healthcare Information Services

View Quarterly Ratios →

P/E Ratio

↑

37.56

↑+32% vs avg

5yr avg: 28.50

062%ile100

30Y Low17.0·High71.7

View P/E History →

EV/EBITDA

↓

17.05

-1% vs avg

5yr avg: 17.26

046%ile100

30Y Low9.6·High35.3

P/FCF

↑

27.96

-9% vs avg

5yr avg: 30.73

054%ile100

30Y Low14.5·High46.6

P/B Ratio

↑

31.26

↑+76% vs avg

5yr avg: 17.76

085%ile100

30Y Low3.9·High56.1

ROE

↑

51.2%

↓+1% vs avg

5yr avg: 50.9%

083%ile100

30Y Low3%·High125%

Debt/EBITDA

↑

2.62

↑+119% vs avg

5yr avg: 1.20

0100%ile100

30Y Low0.0·High2.6

Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.

NRC Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

National Research Corporation trades at 37.6x earnings, 32% above its 5-year average of 28.5x, sitting at the 62nd percentile of its historical range. Compared to the Healthcare sector median P/E of 22.7x, the stock trades at a premium of 65%. On a free-cash-flow basis, the stock trades at 28.0x P/FCF, 9% below the 5-year average of 30.7x.

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Market Cap	$440M	$420M	$419M	$976M	$934M	$1.1B	$1.1B	$1.7B	$1.1B	$941M	$467M
Enterprise Value	$515M	$495M	$479M	$1.0B	$933M	$1.0B	$1.1B	$1.7B	$1.1B	$907M	$437M
P/E Ratio →	37.56	36.10	16.96	31.65	29.37	28.44	29.48	52.33	35.64	71.73	39.58
P/S Ratio	3.20	3.06	2.93	6.57	6.17	7.20	8.24	13.22	8.95	8.01	4.27
P/B Ratio	31.26	30.05	13.39	19.94	12.97	12.47	17.08	51.43	56.11	10.45	5.64
P/FCF	27.96	26.70	21.84	43.70	35.36	26.07	29.97	46.65	31.61	40.44	20.43
P/OCF	16.64	15.89	12.10	25.61	25.77	22.97	27.03	41.34	26.87	33.50	17.41

P/E links to full P/E history page with 30-year chart

NRC EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

National Research Corporation's enterprise value stands at 17.0x EBITDA, roughly in line with its 5-year average of 17.3x. The Healthcare sector median is 14.1x, placing the stock at a 21% premium on an enterprise-value basis.

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
EV / Revenue	—	3.60	3.35	6.79	6.15	7.02	8.23	13.40	8.87	7.72	4.00
EV / EBITDA	17.05	16.39	11.62	21.95	18.00	18.34	21.86	35.30	26.06	23.38	12.34
EV / EBIT	22.80	21.91	13.58	25.16	21.19	20.66	25.35	39.84	30.09	26.52	14.01
EV / FCF	—	31.46	24.98	45.15	35.29	25.44	29.93	47.29	31.33	38.99	19.11

NRC Profitability

Margins and return-on-capital ratios measuring operating efficiency

National Research Corporation earns an operating margin of 16.4%. Operating margins have compressed from 27.0% to 16.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 51.2% is exceptionally high. ROIC of 18.8% represents solid returns on invested capital.

Margins

Full margin charts and quarterly trend are on the Earnings History page

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Gross Margin	56.3%	56.3%	60.2%	62.3%	62.4%	64.6%	63.1%	63.7%	60.2%	58.3%	58.3%
Operating Margin	16.4%	16.4%	24.6%	27.0%	30.7%	34.0%	32.0%	33.6%	29.5%	29.1%	28.5%
Net Profit Margin	8.4%	8.4%	17.3%	20.8%	21.0%	25.3%	28.0%	25.3%	25.1%	19.5%	18.8%

Return on Capital

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
ROE	51.2%	51.2%	61.8%	51.2%	40.4%	50.1%	76.7%	124.7%	55.1%	26.5%	26.1%
ROA	8.7%	8.7%	19.4%	24.5%	22.1%	25.8%	30.5%	29.7%	25.6%	18.5%	16.4%
ROIC	18.8%	18.8%	30.6%	39.6%	53.7%	61.5%	53.9%	98.2%	80.0%	47.2%	53.8%
ROCE	23.2%	23.2%	38.5%	43.7%	43.5%	45.9%	49.0%	64.5%	45.2%	37.2%	35.9%

NRC Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

National Research Corporation carries a Debt/EBITDA ratio of 2.6x, which is moderately leveraged (18% below the sector average of 3.2x). Net debt stands at $75M ($79M total debt minus $4M cash). Interest coverage of 4.7x is adequate, though a cyclical earnings downturn could tighten the margin of safety.

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Debt / Equity	5.65	5.65	2.06	0.80	0.32	0.34	0.52	1.11	0.19	0.01	0.03
Debt / EBITDA	2.62	2.62	1.56	0.85	0.45	0.51	0.66	0.75	0.09	0.03	0.08
Net Debt / Equity	—	5.35	1.92	0.66	-0.02	-0.30	-0.02	0.70	-0.49	-0.37	-0.37
Net Debt / EBITDA	2.48	2.48	1.46	0.70	-0.03	-0.45	-0.03	0.48	-0.23	-0.87	-0.86
Debt / FCF	—	4.76	3.14	1.45	-0.06	-0.63	-0.04	0.64	-0.28	-1.45	-1.33
Interest Coverage	4.75	4.75	13.60	46.50	36.41	30.17	23.87	20.58	23.31	417.30	164.19

NRC Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

The current ratio of 0.55x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.67x to 0.55x over the past 3 years.

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Current Ratio	0.55	0.55	0.55	0.67	1.31	1.82	1.71	0.76	0.60	1.62	1.49
Quick Ratio	0.55	0.55	0.55	0.67	1.31	1.82	1.71	0.76	0.60	1.62	1.49
Cash Ratio	0.11	0.11	0.12	0.18	0.75	1.35	1.09	0.35	0.28	1.07	1.05
Asset Turnover	—	1.02	1.08	1.21	1.16	0.94	1.00	1.16	1.11	0.92	0.91
Inventory Turnover	—	—	—	—	—	—	—	—	—	—	—
Days Sales Outstanding	—	29.51	28.56	31.01	36.84	35.97	42.36	33.68	36.52	47.13	41.46

NRC Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

National Research Corporation returns 7.1% to shareholders annually — split between a 2.5% dividend yield and 4.6% buyback yield. The payout ratio of 94.6% is elevated — while still covered by earnings, there is limited headroom for dividend increases. The earnings yield of 2.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.

Dividends

Full dividend history and growth charts are on the Dividend History page

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Dividend Yield	2.5%	2.6%	2.7%	3.7%	2.2%	0.9%	1.0%	1.9%	1.6%	1.8%	6.1%
Payout Ratio	94.6%	94.6%	46.2%	117.4%	65.9%	24.4%	28.2%	96.6%	56.1%	73.5%	139.2%

Total Shareholder Return Metrics

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Earnings Yield	2.7%	2.8%	5.9%	3.2%	3.4%	3.5%	3.4%	1.9%	2.8%	1.4%	2.5%
FCF Yield	3.6%	3.7%	4.6%	2.3%	2.8%	3.8%	3.3%	2.1%	3.2%	2.5%	4.9%
Buyback Yield	4.6%	4.8%	7.4%	2.0%	3.0%	0.4%	0.0%	0.0%	6.8%	0.2%	0.0%
Total Shareholder Yield	7.1%	7.4%	10.1%	5.7%	5.2%	1.2%	1.0%	1.9%	8.3%	2.0%	6.2%
Shares Outstanding	—	$22M	$24M	$25M	$25M	$26M	$26M	$26M	$28M	$25M	$25M

Peer Comparison

Compare NRC with 10 similar companies in its peer group

Company	Market Cap	P/E	EV/EBITDA	P/FCF	Gross Margin	Op Margin	ROE	ROIC	Debt/EBITDA
NRCYou	$440M	37.6	17.0	28.0	56.3%	16.4%	51.2%	18.8%	2.6
SATS	$37B	-2.6	—	—	37.1%	-118.1%	-178.7%	-32.9%	—
FORR	$135M	-1.1	8.6	7.5	53.3%	0.5%	-67.0%	0.8%	4.3
CSGP	$14B	1939.8	76.8	332.9	75.2%	-2.2%	0.1%	-0.9%	6.7
MORN	$7B	20.5	11.0	15.6	61.0%	21.5%	26.3%	15.3%	2.0
QNST	$719M	155.1	20.5	8.7	10.1%	0.6%	2.0%	2.8%	0.3
HCAT	$102M	-0.5	15.4	—	33.5%	-11.6%	-58.3%	-6.1%	11.9
PINC	$2B	128.5	21.3	7.3	73.4%	0.1%	1.2%	0.0%	2.4
HQY	$7B	35.8	25.0	16.2	69.5%	24.6%	10.2%	8.5%	3.1
TDOC	$1B	-6.7	16.3	4.8	69.5%	-10.4%	-13.9%	-11.5%	10.4
CERT	$905M	-582.0	9.4	9.6	61.5%	5.0%	-0.2%	1.5%	0.1
Healthcare Median	—	22.7	14.1	18.6	64.0%	-4.3%	-32.3%	-11.1%	3.2

Peer selection based on competitive and market overlap. Compare multiple stocks →

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

NRC — Frequently Asked Questions

Quick answers to the most common questions about buying NRC stock.

What is National Research Corporation's P/E ratio?

National Research Corporation's current P/E ratio is 37.6x. The historical average is 38.0x. This places it at the 62th percentile of its historical range.

What is National Research Corporation's EV/EBITDA?

National Research Corporation's current EV/EBITDA is 17.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 18.6x.

What is National Research Corporation's ROE?

National Research Corporation's return on equity (ROE) is 51.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 33.5%.

Is NRC stock overvalued?

Based on historical data, National Research Corporation is trading at a P/E of 37.6x. This is at the 62th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is National Research Corporation's dividend yield?

National Research Corporation's current dividend yield is 2.51% with a payout ratio of 94.6%.

What are National Research Corporation's profit margins?

National Research Corporation has 56.3% gross margin and 16.4% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does National Research Corporation have?

National Research Corporation's Debt/EBITDA ratio is 2.6x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.